Highlights Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Delayed Nasdaq Other stock markets 12:25:38 2024-06-27 EDT			5-day change	1st Jan Change
12.46 ^USD	+2.09%		+8.88%	+32.25%

05-07	JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating	MT
05-06	Transcript : Enanta Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 06, 2024

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M	05-06	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-06	CI
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M	02-07	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-07	CI
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q4 Revenue $18.9M, vs. Street Est of $17.5M	11-20	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	11-20	CI
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	11-20	CI
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q3 Revenue $18.9M, vs. Street Est of $16.7M	23-08-07	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-07	CI
Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus	23-06-20	CI
Enanta Pharmaceuticals Lower Fiscal Q2 Revenue Misses Expectations While Loss Widens Shares Fall Premarket	23-05-09	MT
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.8M, vs. Street Est of $19.1M	23-05-08	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-08	CI
Enanta Pharmaceuticals Says FDA Grants Fast Track Designation for EDP-323	23-04-06	MT
Enanta Pharmaceuticals, Inc. to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research	23-03-14	CI
Enanta Pharmaceuticals' Fiscal Q1 Loss Narrows, Revenue Drops	23-02-07	MT
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $23.6M, vs. Street Est of $22.5M	23-02-07	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-07	CI
Enanta Pharmaceuticals Fiscal Q4 Loss Widens as Revenue Drops	22-11-21	MT
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q4 Revenue $20.3M	22-11-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Highlights

Filters